Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

M&A Fireworks: Shire Buys Jerini For €328 Million

This article was originally published in The Pink Sheet Daily

Executive Summary

Jerini secures a hefty payout, despite FDA deeming HAE candidate Firazyr “not approvable.”

You may also be interested in...



Persistence, Secondary Endpoints Helped Shire Get FDA Nod For Firazyr Novel PRO

FDA questioned the validity of icatibant’s patient-reported outcomes instrument during a first-cycle review and found it “difficult to interpret.” But conducting a third trial and running validity testing after FDA issued final PRO guidance, as well as key secondary endpoints that supported the treatment effect, helped sway regulators.

Shire Seeks Advantage For Firazyr In HAE Through Self-Administration Data In Labeling

An FDA advisory panel will meet June 23 to assess the drug, which would enter a crowded U.S. market for hereditary angioedema.

Shire Seeks Advantage For Firazyr In HAE Through Self-Administration Data In Labeling

An FDA advisory panel will meet June 23 to assess the drug, which would enter a crowded U.S. market for hereditary angioedema.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS068162

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel